stock downgrade
Barclays Downgrades Illumina to Underweight
In Monday morning trading on the Nasdaq, shares of Illumina were down 7 percent at $103.65.
BTIG Downgrades Ginkgo Bioworks to Sell Rating
Last week, Ginkgo reported Q1 revenues of $38 million, down 53 percent from $81 million a year ago, spurring plans to make major changes to its business.
UBS Downgrades QuidelOrtho to Sell
The investment bank cited risks in the firm's guidance for respiratory test sales and in the launch of the Savanna point-of-care MDx system.
Barclays Downgrades Thermo Fisher Scientific, Danaher to Equal Weight
The investment bank also downgraded the US life science tools and diagnostics industry from Positive to Neutral citing macroeconomic uncertainty across end markets.
TD Cowen Downgrades Illumina to Market Perform
The consensus Wall Street estimate for 2024 revenues suggests no growth, analyst Dan Brennan noted, though better margins could help sales rebound in 2025.
Jul 31, 2023
Evercore, Barclays Downgrade Agilent Shares
Oct 14, 2022
Canaccord Downgrades T2 Biosystems to Hold
Jul 26, 2022
Cowen Downgrades Invitae to Market Perform
Mar 15, 2021
Roche to Acquire GenMark Diagnostics for $1.8B
Feb 1, 2021
Oppenheimer Downgrades Invitae to Perform Rating
Nov 24, 2020
BTIG Downgrades Fulgent Genetics from Buy to Neutral
Oct 14, 2020